WALDENSTROM MACROGLOBULINEMIA

This early-stage study is testing a new oral medication called LP-168 in adults whose B-cell blood cancers have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see how the drug behaves in the body. Researchers will also look for e…

This study is testing a new oral medication called AS-1763 (docirbrutinib) for adults with certain blood cancers that have returned or stopped responding to at least two prior treatments. The main goals are to find a safe and effective dose and to see how well the drug works agai…

This early-stage study is testing a new oral medication called SGR-1505 in adults with advanced B-cell cancers that have returned or stopped responding to previous treatments. The main goal is to find the highest safe dose and understand how the drug affects the body. Researchers…

This study is testing whether a combination of two drugs, venetoclax and rituximab, works better than standard chemotherapy for people newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this chemotherapy-free approach can control the …

This study is testing whether combining three medications—pirtobrutinib, venetoclax, and rituximab—can effectively treat people newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. Researchers want to see if this time-limited treatment approach can achieve s…

This study is observing patients with a rare blood cancer called Waldenström macroglobulinemia who are taking the drug zanubrutinib. The goal is to better understand how well the drug works and what side effects patients experience in real-world settings, especially among differe…

This study is testing whether a pill called venetoclax can help control a rare type of blood cancer called Waldenström macroglobulinemia in Japanese adults whose cancer has come back or stopped responding to prior treatments. About 14 participants will take the pill daily, with d…

This study is comparing two different drug combination strategies for people newly diagnosed with a rare, slow-growing blood cancer called Waldenström's macroglobulinemia. About 92 participants will be randomly assigned to receive either a combination of ibrutinib and rituximab (…

This study aims to collect long-term safety and effectiveness data for patients with various blood cancers who are already taking the drug ibrutinib and benefiting from it. It provides continued access to the medication for about 700 participants who were in previous ibrutinib st…

This study is testing whether combining three drugs—zanubrutinib, bendamustine, and rituximab—can effectively control Waldenström macroglobulinemia, a rare blood cancer, in people who have not yet received treatment. About 55 adults with this condition will receive the drug combi…

This study aims to understand and better manage high blood pressure and heart risks in people with certain blood cancers who are taking a specific type of medication called a BTK inhibitor. Researchers will closely monitor 100 patients for one year to see how often these side eff…

This study is testing an experimental drug called epcoritamab in patients with Waldenstrom Macroglobulinemia, a rare blood cancer, who have already tried other treatments. The drug is a type of antibody designed to help the patient's own immune system find and attack cancer cells…

This study aims to understand why some early, non-symptomatic blood conditions turn into cancer. Researchers will observe 10,000 adults who have these early conditions or a history of cancer. They will analyze genetic material from routine blood and tissue samples to identify cha…

This study aims to see if a simple blood test can predict whether a rare blood cancer called Waldenström's disease will come back after treatment. Researchers will test 90 patients who have finished their first 6 months of therapy. The goal is to learn if tiny pieces of cancer DN…

This study aims to create a national Spanish registry of patients diagnosed with Waldenström's macroglobulinemia, a rare blood cancer, over the past 30 years. By looking back at the medical records of up to 1,000 patients, researchers want to understand the disease better, see wh…

This study aims to learn how certain blood cancers develop and change over time. Researchers will follow up to 1,000 adults who have been diagnosed with these conditions, collecting blood and tissue samples regularly. The goal is to understand the biology of these diseases to hel…